Introduction: Given the elevated dementia risk in underrepresented demographic groups in the US—particularly in Latino and Non-Latino Black individuals compared to Non-Latino White individuals—it is v
We investigate whether increased racial diversity of clinical trial principal investigators could increase the enrollment of Black patients, which currently lags population and disease-burden shares.